Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Methylene blue for intractable pain from oral mucositis related to cancer treatment: a randomized phase 2 clinical trial

Fig. 2

Changes in numeric rating scale (NRS) of pain scores over the first 2 days of treatment. Mean reduction in numeric pain scores at day 2 after the start of treatment were significantly or marginally better in patients who received conventional therapy plus methylene blue (MB) oral rinse at three different concentrations than in patients who received conventional therapy alone (Tukey pairwise comparison; P = 0.0071, P = 0.0506, P = 0.0114)

Back to article page